# US 2010/0168038 A1 · Use of compounds in combination with gamma-irradiation for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168038 A1
- Document ID: US20100168038A1
- Status: Published application
- Kind: A1
- Application number: 12/160,787
- Filed: 2007-01-15
- Published: 2010-07-01
- Earliest claimed: 2006-01-13
- Inventors: Rickard Glas; Hong Xu
- Web page: https://patentgrep.com/patent/US20100168038A1

## CPC

- A61K 38/06: Tripeptides
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

TPP II (tripeptidyl peptidase inhibitors are useful in enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells. Suitable compounds comprise tripeptide compounds of general formula RN1RN2N-A1-A2-A3-CO—RC1 wherein RN1, RN2, A1, A2, A3 and RC1 are as defined herein, and which include for example the tripeptide sequences GLA and GPG. Complete in vivo tumor regression in mice injected with TPPII inhibitors is observed, during treatment in combination with gamma-irradiation.

## Claims

### Claim 1

A method of enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells comprising administering to a patient in need thereof a therapeutically effective amount of a TPP II inhibitor compound.

### Claim 2 (depends on 1)

A method as claimed in claim 1, wherein said compound is selected from formula (i) or is a pharmaceutically acceptable salt thereof:
RN1RN2N A1-A2-A3-CO—RC1 (i)
wherein A1, A2 and A3 are amino acid residues having the following definitions according to the standard one-letter amino acid abbreviations or names:
A1 is G, A, V, L, I, P, 2-aminobutyric acid, norvaline or tert-butyl glycine,
A2 is G, A, V, L, I, P, F, W, C, S, K, R, 2-aminobutyric acid, norvaline, norleucine, tert-butyl alanine, alpha-methyl leucine, 4,5-dehydro-leucine, allo-isoleucine, alpha-methyl valine, tert-butyl glycine, 2-allylglycine, ornithine or alpha, gamma-diaminobutyric acid,
A3 is G, A, V, L, I, P, F, W, D, E, Y, 2-aminobutyric acid, norvaline or tert-butyl glycine,
RN1 and RN2 are each attached to the N terminus of the peptide, are the same or different, and are each independently
RN3,
(linker1)-RN3,
CO-(linker1)-RN3,
CO—O-(linker1)-RN3,
CO—N-((linker1)-RN3))RN4 or
SO2—(linker1)-RN3,
(linker 1) may be a single bond, or CH2, CH2CH2, CH2CH2CH2, CH2CH2CH2CH2 or CH═CH,
RN3 and RN4 are the same or different and are hydrogen or any of the following optionally substituted groups:
saturated or unsaturated, branched or unbranched C1-6 alkyl;
saturated or unsaturated, branched or unbranched C3-12 cycloalkyl;
benzyl;
phenyl;
naphthyl;
mono- or bicyclic C1-10 heteroaryl; or
non-aromatic C1-10 heterocyclyl;
wherein there may be zero, one or two same or different optional substituents on RN3 and/or RN4 which may be:
hydroxy-;
thio-:
amino-;
carboxylic acid;
saturated or unsaturated, branched or unbranched C1-6 alkyloxy;
saturated or unsaturated, branched or unbranched C3-12 cycloalkyl;
N—, O—, or S— acetyl;
carboxylic acid saturated or unsaturated, branched or unbranched C1-6 alkyl ester;
carboxylic acid saturated or unsaturated, branched or unbranched C3-12 cycloalkyl ester
phenyl;
mono- or bicyclic C1-10 heteroaryl;
non-aromatic C1-10 heterocyclyl; or
halogen; and
RC1 is attached to the C terminus of the tripeptide, and is:
O—Rc2,
O-(linker2)-RC2,
N((linker2)RC2)RC3, or
N(linker2)RC2—NRC3RC4,
wherein (linker2) may be a single bond, or C1-6 alkyl or C2-4 alkenyl, and
RC2, RC3 and RC4 are the same or different, and are hydrogen or any of the following optionally substituted groups:
saturated or unsaturated, branched or unbranched C1-6 alkyl;
saturated or unsaturated, branched or unbranched C3-12 cycloalkyl;
benzyl;
phenyl;
naphthyl;
mono- or bicyclic C1-10 heteroaryl; or
non-aromatic C1-10 heterocyclyl;
wherein there may be zero, one or two same or different optional substituents on each of RC2 and/or RC3 and/or RC4 which may be one or more of:
hydroxy-;
thio-:
amino-;
carboxylic acid;
saturated or unsaturated, branched or unbranched C1-6 alkyloxy;
saturated or unsaturated, branched or unbranched C3-12 cycloalkyl;
N—, O—, or S— acetyl;
carboxylic acid saturated or unsaturated, branched or unbranched C1-6 alkyl ester;
carboxylic acid saturated or unsaturated, branched or unbranched C3-12 cycloalkyl ester
phenyl;
halogen;
mono- or bicyclic C1-10 heteroaryl; or
non-aromatic C1-10 heterocyclyl.

### Claim 3 (depends on 2)

A method as claimed in claim 2 wherein said compound of formula (i) is such that:
RN1 is hydrogen,
RN2 is hydrogen, C(═O)—O-saturated or unsaturated, branched or unbranched, C1-4 alkyl, optionally substituted with phenyl or 2-furyl, or C(═O)— saturated or unsaturated, branched or unbranched, C1-4 alkyl, optionally substituted with phenyl or 2-furyl, and
RC1 is OH, O—C1-6 alkyl, O—C1-6 alkyl-phenyl, NH—C1-6 alkyl, or NH—C1-6 alkyl-phenyl.

### Claim 4 (depends on 3)

A method as claimed in claim 3, wherein said compound of formula (i) is such that:
A1 is G, A or 2-aminobutyric acid,
A2 is L, I, norleucine, V, norvaline, tert-butyl alanine, 4,5-dehydro-leucine, allo-isoleucine, 2-allylglycine, P, 2-aminobutyric acid, alpha-methyl leucine, alpha-methyl valine or tert-butyl glycine,
A3 is G, A, V, P, 2-aminobutyric acid or norvaline,
RN1 is H,
RN2 is hydrogen, C(═O)—O-saturated or unsaturated, branched or unbranched, C1-4 alkyl, optionally substituted with phenyl or 2-furyl, or C(═O)— saturated or unsaturated, branched or unbranched, C1-4 alkyl, optionally substituted with phenyl or 2-furyl, and
RC1 is OH, O—C1-6 alkyl, O—C1-6 alkyl-phenyl, NH—C1-6 alkyl, or NH—C1-6 alkyl-phenyl.

### Claim 5 (depends on 4)

A method as claimed in claim 4, wherein said compound of formula (i) is such that:
A1 is G, A or 2-aminobutyric acid,
A2 is L, I, norleucine, V, norvaline, tert-butyl alanine, 4,5-dehydro-leucine, allo-isoleucine or 2-allylglycine,
A3 is G, A, V, P, 2-aminobutyric acid or norvaline,
RN1 is H,
RN2 is hydrogen, C(═O)—O-saturated or unsaturated, branched or unbranched, C1-4 alkyl, optionally substituted with phenyl or 2-furyl, or C(═O)— saturated or unsaturated, branched or unbranched, C1-4 alkyl, optionally substituted with phenyl or 2-furyl, and
RC1 is OH, O—C1-6 alkyl, O—C1-6 alkyl-phenyl, NH—C1-6 alkyl, or NH—C1-6 alkyl-phenyl.

### Claim 6 (depends on 5)

A method as claimed in claim 5 wherein said compound of formula (i) is such that:
A1 is G or A,
A2 is L, I, or norleucine,
A3 is G or A,
RN1 is hydrogen,
RN2 is hydrogen, C(═O)—O-saturated or unsaturated, branched or unbranched, C1-4 alkyl, optionally substituted with phenyl or 2-furyl, or C(═O)— saturated or unsaturated, branched or unbranched, C1-4 alkyl, optionally substituted with phenyl or 2-furyl, and
RC1 is OH, O—C1-6 alkyl, O—C1-6 alkyl-phenyl, NH—C1-6 alkyl, or NH—C1-6 alkyl-phenyl.

### Claim 7 (depends on 2, 3, 4, 5, 6)

A method as claimed in any of claims 2 to 6 wherein
RN1 is hydrogen,
RN2 is hydrogen, C(═O)—OCH2Ph or C(═O)—CH═CH-(2-furyl), and
RC1 is OH, O—C1-6 alkyl, or NH—C1-6 alkyl.

### Claim 8 (depends on 7)

A method as claimed in claim 7 wherein said compound of formula (i) is Z-GLA-OH, Bn-GLA-OH, FA-GLA-OH or H-GLA-OH.

### Claim 9 (depends on 8)

A method as claimed in claim 8 wherein said compound of formula (i) is Z-GLA-OH.

### Claim 10 (depends on 2)

A method as claimed in claim 2 wherein A1 is G, A or 2-aminobutyric acid.

### Claim 11 (depends on 10)

A method as claimed in claim 10 wherein A1 is G or A.

### Claim 12 (depends on 2)

A method as claimed in claim 2, wherein A2 is L, I, norleucine, V, norvaline, tert-butyl alanine, 4,5-dehydro-leucine, allo-isoleucine, 2-allylglycine, P, K, 2-aminobutyric acid, alpha-methyl leucine, alpha-methyl valine or tert-butyl glycine.

### Claim 13 (depends on 12)

A method as claimed in claim 12 wherein A2 is L, I, norleucine, V, norvaline, tert-butyl alanine, 4,5-dehydro-leucine, allo-isoleucine, 2-allylglycine, P or K.

### Claim 14 (depends on 13)

A method as claimed in claim 13 wherein A2 is L, I, norleucine, P or K.

### Claim 15 (depends on 14)

A method as claimed in claim 14 wherein A2 is L or P.

### Claim 16 (depends on 15)

A method as claimed in claim 15 wherein A2 is P.

### Claim 17 (depends on 2)

A method as claimed in claim 2 wherein A3 is G, A, V, P, 2-aminobutyric acid or norvaline.

### Claim 18 (depends on 17)

A method as claimed in claim 17 wherein A3 is G or A.

### Claim 19 (depends on 2)

A method as claimed in claim 2 wherein RN1 is hydrogen.

### Claim 20 (depends on 2)

A method as claimed in claim 2 wherein RN2 is
RN3,
(linker1)-RN3,
CO-(linker1)-RN3, or
CO—O-(linker1)-RN3,
wherein
(linker1) may be a single bond, or CH2, CH2CH2, CH2CH2CH2, CH2CH2CH2CH2 or CH═CH, and
RN3 is hydrogen or any of the following unsubstituted groups:
saturated or unsaturated, branched or unbranched C1-4 alkyl;
benzyl;
phenyl; or
monocyclic heteroaryl.

### Claim 21 (depends on 20)

A method as claimed in claim 20 wherein RN2 is hydrogen, benzyloxycarbonyl, benzyl, benzoyl, tert-butyloxycarbonyl, 9-fluorenylmeth-oxycarbonyl or FA.

### Claim 22 (depends on 21)

A method as claimed in claim 21 wherein RN2 is hydrogen, benzyloxycarbonyl or FA.

### Claim 23 (depends on 2)

A method as claimed in claim 2 wherein RC1 is:
O—RC2,
O-(linker2)-RC2, or
NH-(linker2)RC2
wherein
(linker2) may be a single bond, C1-6 alkyl or C2-4 alkenyl, and
RC2 is hydrogen or any of the following unsubstituted groups:
saturated or unsaturated, branched or unbranched C1-5 alkyl;
benzyl;
phenyl; or
monocyclic C1-10 heteroaryl.

### Claim 24 (depends on 23)

A method as claimed in claim 23 wherein RC1 is OH, O—C1-6 alkyl, O—C1-6 alkyl-phenyl, NH2, NH—C1-6 alkyl, or NH—C1-6 alkyl-phenyl.

### Claim 25 (depends on 24)

A method as claimed in claim 24 wherein RC1 is OH, O—C1-6 alkyl, NH2, or NH—C1-6 alkyl.

### Claim 26 (depends on 25)

A method as claimed in claim 25 wherein RC1 is OH or NH2.

### Claim 27 (depends on 26)

A method as claimed in claim 26 wherein RC1 is NH2.

### Claim 28 (depends on 2)

A method as claimed in claim 2 wherein said compound is GPG-NH2, Z-GPG-NH2, Bn-GPG-NH2, FA-GPG-NH2, GPG-OH, Z-GPG-OH, Bn-GPG-OH, or FA-GPG-OH.

### Claim 29 (depends on 28)

A method as claimed in claim 28 wherein said compound is GPG-NH2.

### Claim 30 (depends on 2)

A method as claimed in claim 2 wherein said compound is ALG-NH2, Z-ALG-NH2, Bn-ALG-NH2, FA-ALG-NH2, ALG-OH, Z-ALG-OH, Bn-ALG-OH, or FA-ALG-OH.

### Claim 31 (depends on 30)

A method as claimed in claim 30 wherein said compound is ALG-NH2.

### Claim at position 32

32-36. (canceled)

### Claim 37

A method for identifying a compound suitable for enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells comprising contacting TPP II with a compound to be screened, and identifying whether the compound inhibits the activity of TPP II.

### Claim 38 (depends on 2)

A pharmaceutical composition comprising a compound of formula (i) as defined in claim 2 and a pharmaceutically acceptable diluent or carrier, with the proviso that said compound is not selected from any of the following:
(a) GPE-OH;
(b) a compound of the formula
Wherein X′ represents OH, (C1-5)alkoxy, NH2, NH—C1-5-alkyl, N(C1-5 alkyl)2;
R1′ is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C1-5)alkoxy group, a (C1-5)alkyl group or a halogen atom, and Ala, Val, Leu, or Ile;
R2′ is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn;
R3′ and R4′ independently represent H, OH, (C1-5)alkyl, or (C1-5)alkoxy, provided that R3′ and R4′ are not both OH or (C1-5)alkoxy;
R5′ represents H, OH, (C1-5)alkyl or (C1-5)alkoxy;
and wherein R0′ represents a group of the formula
wherein Y′ represents —CO—, —CH2CO—, —CH2CH2CO—, —CH2CH2CH2CO—, —CH═CH—CO or —OCH2CO—, and wherein Z′ represents a halogen atom, a trifluormethyl group, (C1-4) alkoxy group, (C1-4) alkyl group; or wherein two neighbouring substituents may form a (C1-3) alkylene-dioxy group; and wherein n′ is 0 or an integer of from 1 to 5;
(c) X″-PG-NH2, wherein X″ is an amino acid residue;
(d) PGP-OH;
(e) any of the following compounds
GPG-NH2
GKG-NH2
CQG-NH2
RQG-NH2
KQG-NH2
ALG-NH2
GVG-NH2
VGG-NH2
ASG-NH2
SLG-NH2
SPT-NH2;
(f) any of the following compounds
AIG-NH2
GFG-NH2
GWG-NH2
FLG-NH2
GYG-NH2
APG-NH2
GLG-NH2
tBu-GPG-NH2
(g) LAP-OH
(h) a compound comprising the sequence GPX′″ wherein X′″ is an amino acid
(i) IVY-OH
(j) GFE-OH
(k) any of the following compounds
VPP-OH
IPP-OH
(l) PRG-NH2; and
(m) any of the following compounds
PLG-NH2
PAG-NH2
GPG-OH
PG-ARG-NH2
GPA-NH2
GGG-NH2
LKA-NH2
ILK-NH2
GPQ—NH2
GHK-NH2
ACQ—NH2
ARV-NH2
KAR-NH2
HKA-NH2
GAT-NH2
KAL-NH2
PGR-NH2
GhydPG-NH2
tBu-GLG-NH2
metALG-NH2 and
LNF-NH2.

### Claim at position 35

39-42. (canceled)

### Claim 43 (depends on 6)

A pharmaceutical composition comprising a compound as defined in claim 6 and a pharmaceutically acceptable diluent or carrier.

### Claim at position 37

44-45. (canceled)
